Alan Schwartz, MD
Internal Medicine · Santa Ana, CANPI 1023183480
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $318 of the $446 with a category attached, or 71.3%. Novartis accounts for 77.8% of it on its own, with 1 other manufacturer making up the rest.
Across 4 payments — averaging $111.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$347
- AstraZeneca$99
Across 34 payments — averaging $29,815 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$967K
- GSK$47K
What the payments were for
- Travel & lodging$12829%
- Food & beverage$31871%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 3 | $347 |
| AstraZeneca | 1 | $99 |
How this compares
$446 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 70 | $71,574 |
| JardianceEmpagliflozin | 83 | $58,501 |
| TrulicityDulaglutide | 23 | $22,801 |
| OzempicSemaglutide | 18 | $17,070 |
| EliquisApixaban | 12 | $7,007 |
| AlogliptinAlogliptin Benzoate | 14 | $2,609 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $2,256 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 68 | $1,844 |
| Levemir FlexpenInsulin Detemir | 11 | $1,668 |
| SynthroidLevothyroxine Sodium | 18 | $1,139 |
| Metformin Hcl | 145 | $932 |
| Atorvastatin Calcium | 128 | $897 |
| Losartan Potassium | 73 | $879 |
| Naproxen | 60 | $741 |
| Amlodipine Besylate | 118 | $706 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Santa Ana
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.